Besides endothelial cells, platelets possess active nitric oxide synthase (NOS) enzyme, which converts L-arginine to NO and L-citrulline. Nitroglycerin (NTG) inhibits platelet aggregation by increasing intracellular cGMP levels, an effect similar to that of NO. In this study we examined the regulation of platelet NOS activity by NTG and authentic NO.
Methods and Results
Nitric oxide synthase activity was measured as formation of L-citrulline from L-arginine. As expected, incubation of platelet-rich plasma with NTG resulted in a concentration-dependent (40-400 μmol/L) increase in nitrite levels and an increase in cGMP accumulation. Concurrently, NTG was found to exert an inhibitory effect on platelet NOS activity. Exposure of washed platelets to authentic NO also resulted in 50% decrease in NOS activity. Western analysis showed that NTG and authentic NO had no effect on NOS protein expression in human platelets.
Conclusions
This study indicates that NO, either authentic or derived from NTG, decreases NOS activity without affecting NOS protein expression in human platelets. The downregulation of NOS activity may have a bearing on the phenomenon of nitrate tolerance.
NakaneM, SchmidtHHHW, PollockJS, ForstermannU, MuradF.Cloned human brain nitric oxide synthase is highly expressed in skeletal muscle. FEBS Lett1993;316:175–80.
2.
JanssensSP, ShimouchiA, QuertermousT, BlochDB, BlochKD.Cloning and expression of a cDNA encoding human endothelium-derived relaxing factor/nitric oxide synthase. J Biol Chem1992;267:14519–22.
3.
GellerDA, LowensteinCJ, ShapiroRA, NusslerAK, DiSilvioM, WangSC, NakaymaDK, SimmonsRL, SnyderSH, BilliarTR.Molecular cloning and expression of inducible nitric oxide synthase from human hepatocytes. Proc Natl Acad Sci USA1993;90:3491–5.
4.
WhiteKA, MarlettaMA.Nitric oxide synthase is a cytochrome P-450 type hemoptotein. Biochemistry1992;31:6627–31.
5.
StuehrDJ, Ikeda-SaitoM.Spectral characterization of brain and macrophage nitric oxide synthases: cytochrome P-450-like heme-proteins that contain a flavin semiquinone radical. J Biol Chem1992;267:20547–50.
6.
BredtDS, SnyderSH.Nitric oxide mediates glutamate-linked enhancement of cGMP levels in the cerebellum. Proc Natl Acad Sci USA1989;86:9030–3.
7.
BushPA, GonzalezNE, IgnarroLJ.Biosynthesis of nitric oxide and citrulline from L-arginine by constitutive nitric oxide synthase present in rabbit corpus cavernosum. Biochem Biophys Res Commun1992;186:308–14.
8.
RogersNE, IgnarroLJ.Constitutive nitric oxide synthase from cerebellum is reversibly inhibited by nitric oxide from L-arginine. Biochem Biophys Res Commun1992;189:242–9.
9.
RadomskiMW, PalmerRMJ, MoncadaS.An L-arginine nitric-oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci USA1990;87:5193–7.
10.
RadomskiMW, PalmerRMJ, MoncadaS.Characterization of the L-arginine nitric oxide pathway in human platelets. Br J Pharmacol1990;101:325–8.
11.
ChenLY, MehtaP, MehtaJL.Oxidized-LDL decreases L-arginine uptake and nitric oxide synthase protein expression in human platelets: relevance in the effect of oxidized-LDL on platelet function. Circulation1996;93:1740–6.
12.
MehtaJL, ChenLY, MehtaP, KoneBC, TurnerP.Identification of constitutive and inducible forms of nitric oxide synthase in human platelets. J Lab Clin Med1995;125:370–7.
13.
MellionBT, IgnarroLJ, OhlsteinEH, PontecorvoEG, HymanAL, KadowitzPJ.Evidence for the inhibitory role of guanosine 3’,5'-monophosphate in ADP-induced human platelet aggregation in the presence of nitric oxide and related vasodilators. Blood1981;57:946–55.
14.
MellionBT, IgnarroLJ, MyersCB, OhlsteinEH, BallotBA, HymanAL, KadowitzPJ.Inhibition of human platelet aggregation by S-nitrosothiols. Heme-dependent activation of soluble guanylate cyclase and stimulation of cyclic GMP accumulation. Mol Pharmacol1983;23:653–64.
15.
MehtaJL, MehtaP.Comparative effects of nitroprusside and nitroglycerin on platelet aggregation in patients with heart failure. J Cardiovasc Pharmacol1980;2:25–33.
16.
ChenLY, MehtaJL.Lys- and glu-plasminogen potentiate the inhibitory effect of recombinant tissue plasminogen activator on human platelet aggregation. Thromb Res1994;74:555–63.
17.
DamianiP, BuriniG.Fluorometric determination of nitrite. Talanta1986;33:649–52.
18.
NicoliniFA, WilsonAC, MehtaP, MehtaJL.Comparative platelet inhibitory effects of human neutrophils and lymphocytes. J Lab Clin Med1990;116:147–52.
19.
MehtaJL, ChenLY.Reversal by high-density lipoprotein of the effect of oxidized low-density lipoprotein on nitric oxide synthase protein expression in human platelets. J Lab Clin Med1996;127:287–95.
20.
RengasamyA, JohnsRA.Regulation of nitric oxide synthase by nitric oxide. Mol Pharmacol1993;44:124–8.
21.
BugaGM, GriscavageJM, RogersNE, IgnarroLJ.Negative feedback regulation of endothelial cell function by nitric oxide. Circ Res1993;73:808–12.
22.
SandersKM, WardSM.Nitric oxide as a mediator of nonadrenergic noncholinergic neurotransmission. Am J Physiol1992;262:G379–92.
23.
RajferJ, AronsonWJ, BushPA, DoreyFJ, IgnarroLJ.Nitric oxide as a mediator of relaxation of corpus caversum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med1992;326:90–4.
24.
ChenLY, MehtaJL.Antiplatelet effect of nitroglycerin is primarily mediated by glutathione-s-transferases in human plasma. J Am Coll Cardiol1996;27:302A.
25.
NeedlemanP, JohnsonEM.JrMechanism of tolerance development to organic nitrates. J Pharmacol Exp Therap1972;184:709–15.
26.
BoesgaardS, AldershvileJ, PoulsenHE, LoftS, AndersonME, MeisterA.Nitrate tolerance in vivo is not associated with depletion of arterial or venous thiol levels. Circ Res1994;74:115–20.
27.
LawsonDL, HaughtWH, MehtaP, MehtaJL.Studies on vascular tolerance to nitroglycerin: effects of NG-acetylcysteine, NG-monomethyl L-arginine and endothelin-1. J Cardiovasc Pharmacol In press.
28.
MuzelT, SayeghH, FreemanBA, TarpeyMM, HarrisonD.Evidence for enhanced vascular superoxide anion production in nitrate tolerance. J Clin Invest1995;95:187–94.
